AuthorisedPhase I and Phase II (Integrated)- OtherInterventional

A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs

This early-stage clinical trial is studying a new experimental medicine called KB707. It is designed for adults who have advanced solid cancer tumours that have spread to or started in the lungs. Unlike most cancer treatments given into a vein or taken as a pill, KB707 is breathed directly into the lungs. In some parts of the trial, patients will receive KB707 on its own, while others may receive it alongside docetaxel, a standard chemotherapy drug. The main purpose of the study is safety. Doctors want to find out what side effects the medicine causes, discover the safest dose, and see how well it works at shrinking tumours or slowing cancer growth. Taking part involves regular hospital visits, breathing treatments, blood tests, and scans so the medical team can watch your health very closely.

At a glance

Status

Authorised

Phase

Phase I and Phase II (Integrated)- Other

Sponsor

Krystal Biotech Inc.

Enrolment target

Start

30 Jun 2026

solid tumor

What is this study about?

When cancer affects the lungs, it can be hard to treat. Many standard cancer medicines travel through the whole bloodstream. This means only a small amount reaches the lung tumours, while the rest of the body can suffer side effects. This study tests a new medicine called KB707, which is breathed straight into the lungs. Doctors hope this direct approach delivers treatment right where it is needed most.

The trial is divided into Phase 1 and Phase 2. Phase 1 is about safety. The doctors start with low doses of inhaled KB707 and slowly increase the amount in small groups of patients to find the safest dose. In Phase 2, researchers look more closely at whether the medicine actually helps shrink tumours, stop them from growing, and help people live longer.

Some patients in the study might also be given a chemotherapy drug called docetaxel alongside KB707. By combining these treatments, researchers hope to see if they work better together than standard care alone. The results could help doctors discover a brand-new, more targeted way to help people with advanced lung tumours in the future.

Key takeaways

Tests an experimental inhaled medicine called KB707 for cancers affecting the lungs.
Aims to deliver cancer treatment directly to the lungs to improve effectiveness.
Open to adults aged 18 and older with advanced solid tumours.
Some patients will receive KB707 alone, while others may also receive chemotherapy.
Primary focus is finding a safe dose and checking for side effects.

Who may be eligible?

This study is open to men and women aged 18 and over who have an advanced solid tumour affecting their lungs. An advanced solid tumour means a cancer lump that has grown or spread, and where standard treatments may no longer be working well.

To be considered, you will need to have a good level of day-to-day fitness and be able to inhale medicine properly into your lungs. You will also need to have healthy enough kidney, liver, and heart function to cope with the trial treatments.

You might not be able to join if you have certain severe lung problems (aside from your cancer), active infections, or other serious health conditions that could make taking part unsafe. The study team will review your full medical history and recent scans to make sure it is safe for you to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

I am aged 18 or older.
I have been diagnosed with an advanced solid cancer that affects my lungs.
My current cancer treatment is no longer working, or I need a new treatment option.
I am well enough to carry out daily activities and attend regular hospital visits.
I am able to use a nebuliser or breathing device to inhale medicine.

Answer every question to see your result.

What does participation involve?

If you take part, you will visit a specialist hospital clinic regularly. At your first visits, the team will run tests, such as blood tests, heart checks, and chest scans, to confirm the study is right for you. You will be shown how to breathe in the KB707 treatment using a special breathing device. If you are also having docetaxel, this will be given through a drip into your vein. Throughout the trial, you will have frequent check-ups and scans to monitor your tumours and watch for any side effects. You will stay in the study for as long as the treatment helps you and remains safe, followed by regular check-ins with the study team.

Potential risks and benefits

The main benefit of taking part is the chance that this new medicine might help shrink or control your cancer, while helping doctors learn how to treat lung tumours more effectively in future. However, because KB707 is an experimental drug, there is no guarantee it will work for you. Inhaling the medicine may cause side effects, such as coughing, throat irritation, or breathlessness, and docetaxel can cause tiredness, sickness, and low blood cell counts. You will be closely monitored, and you are free to leave the trial at any time without your regular NHS cancer care being affected.

Locations (2)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
France
—
Unverified
Spain

Common questions

How is KB707 given to patients?

KB707 is an inhaled medicine. You breathe it directly into your lungs through a special mask or mouthpiece, similar to how asthma treatments are given.

Will I have to pay to take part?

No. The trial medicine and all study tests are provided free of charge, and some trials can help cover your travel costs.

Can I carry on taking my normal medicines?

You must tell the study doctors about all medicines you take. They will check to ensure your routine medicines do not clash with the trial treatment.

What happens if the treatment does not work for me?

If scans show your cancer is growing or if the side effects become too uncomfortable, the trial team will stop the treatment and discuss other care options with you.

Can I leave the study if I change my mind?

Yes. Taking part is completely voluntary. You can withdraw at any time, for any reason, and your medical team will continue to care for you.